| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S16079 R66727 |
Christensen (Valproate) (Epilepsy) (Controls exposed to LTG), 2024 | Microcephaly (z-score for head circumference ≤3rd percentile for gestational week, sex, and country (including newborns with congenital malformations)) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.21 [0.90;1.62] C excluded (control group) |
67/1,953 151/5,299 | 218 | 1,953 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S16023 R66515 |
Christensen (Valproate) (Epilepsy) (Controls unexposed, general population), 2024 | Microcephaly (z-score for head circumference ≤3rd percentile for gestational week, sex, and country (including newborns with congenital malformations)) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.06 [0.78;1.45] | 67/1,953 699/22,227 | 766 | 1,953 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6416 R17615 |
Pennell (Valproate), 2012 | Microcephaly at birth (head circumference < 3 percentile) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.27 [0.34;4.83] C | 4/38 6/71 | 10 | 38 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S371 R18374 |
Kini (Valproate) (Controls unexposed, sick), 2006 | Head circumference in children aged between 6 months and 16 years <3rd centile | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 1.66 [0.46;5.96] C | 5/63 5/101 | 10 | 63 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6435 R17691 |
Battino (Valproate), 1999 | Small head circumferences (at birth < 10th percentile) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 0.68 [0.14;3.26] C | 4/57 3/30 | 7 | 57 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6777 R19137 |
Díaz-Romero (Valproate), 1999 | Head circumference <2 SD at birth (measured by a physician and correlated with sex and with gestational age) | during pregnancy (anytime or not specified) | cohort | unexposed, sick | Adjustment: No | 0.79 [0.01;44.65] C | 0/10 0/8 | 0 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5702 R19483 |
Dravet (Valproate), 1992 | Isolated microcephaly at birth (head circumference >2 SD lower than those given in the reference tables adjusted for gestational age at birth) | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 3.12 [0.34;28.74] C | 6/31 1/14 | 7 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.09 [0.82;1.46] | 800 | 2,152 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Valproate) (Epilepsy) (Controls unexposed, general population; 2: Valproate; 3: Valproate) (Controls unexposed, sick; 4: Valproate; 5: Valproate; 6: Valproate;
Asymetry test p-value = 0.4801 (by Egger's regression)
slope=0.0203 (0.1269); intercept=0.2765 (0.3554); t=0.7779; p=0.4801
excluded 16079